RT Journal Article
T1 Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients.
A1 Padillo-Ruiz, Javier
A1 Suarez, Gonzalo
A1 Pereira, Sheila
A1 Calero-Castro, Francisco Jose
A1 Tinoco, Jose
A1 Marin, Luis
A1 Bernal, Carmen
A1 Cepeda-Franco, Carmen
A1 Alamo, Jose Maria
A1 Almoguera, Francisco
A1 Macher, Hada C
A1 Villanueva, Paula
A1 Garcia-Fernandez, Francisco Jose
A1 Gallego, Inmaculada
A1 Romero, Manuel
A1 Gomez-Bravo, Miguel Angel
A1 Denninghoff, Valeria
A1 Serrano, María Jose
K1 central venous catheter
K1 circulating tumor cell
K1 cluster
K1 death risk stratification
K1 early stage
K1 pancreatic cancer
K1 portal vein
AB Effective biomarkers are needed to enable personalized medicine for pancreatic cancer patients. This study analyzes the prognostic value, in early pancreatic cancer, of single circulating tumor cell (CTC) and CTC clusters from the central venous catheter (CVC) and portal blood (PV). In total, 7 mL of PV and CVC blood from 35 patients with early pancreatic cancer were analyzed. CTC were isolated using a positive immunomagnetic selection. The detection and identification of CTC were performed by immunocytochemistry (ICC) and were analyzed by Epi-fluorescence and confocal microscopy. CTC and the clusters were detected both in PV and CVC. In both samples, the CTC number per cluster was higher in patients with grade three or poorly differentiated tumors (G3) than in patients with well (G1) or moderately (G2) differentiated. Patients with fewer than 185 CTC in PV exhibited a longer OS than patients with more than 185 CTC (24.5 vs. 10.0 months; p = 0.018). Similarly, patients with fewer than 15 clusters in PV showed a longer OS than patients with more than 15 clusters (19 vs. 10 months; p = 0.004). These significant correlations were not observed in CVC analyses. CTC presence in PV could be an important prognostic factor to predict poor prognosis in early pancreatic cancer. In addition, the number of clustered-CTC correlate to a tumor negative differentiation degree and, therefore, could be used as a diagnostic biomarker for pancreatic cancer.
PB MDPI AG
SN 2072-6694
YR 2021
FD 2021-12-07
LK https://hdl.handle.net/10668/26368
UL https://hdl.handle.net/10668/26368
LA en
NO Padillo-Ruiz J, Suarez G, Pereira S, Calero-Castro FJ, Tinoco J, Marin L, et al. Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients. Cancers (Basel). 2021 Dec 7;13(24):6153.
DS RISalud
RD Apr 12, 2025